Pay in installments of $32.00 with
,
and
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
For Your Every Summer RSVP, with Code: SUMMER15
Description
Cells at Work! Omnibus 1 (Vols. 1-3)By: Akane Shimizu Series: Cells at Work! Omnibus Get swept away by the drama in your own bloodstream, with the acclaimed manga that inspired the hit anime. The complete series is now available in these two oversized, 600 page volumes! Hailed by doctors and educators for its fun and accurate depictions, Cells at Work! follows the spunky Red Blood Cell and cold as ice White Blood Cell as they navigate all manner of health problems from the inside out.
By: Akane Shimizu | Series: Cells at Work! OmnibusGet swept away by the drama in your own bloodstream, with the acclaimed manga that inspired the hit anime. The complete series is now available in these two oversized, 600-page volumes!
Hailed by doctors and educators for its fun and accurate depictions, Cells at Work! follows the spunky Red Blood Cell and cold-as-ice White Blood Cell as they navigate all manner of health problems from the inside out.
Includes Vol. 1-3 of Cells at Work!
Follow the 37 trillion cells inside a human body, including Red Blood Cell, White Blood Cell, Macrophage, and, of course, the cute, little Platelets, as they face off against threats like cedar pollen, parasites, food poisoning, staph infection, and their ultimate nemesis, cancer. Twenty-four hours a day, 365 days a year, these tiny workers are doing their best to keep you moving.
This new omnibus edition brings the series back in a larger page size, with three volumes in one. Collect the entire series in just two books!
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
4.2 ★★★★★
Based on 26 reviews
Sort
Product Reviews
★★★★★ 4
Cute but a little stiff
These are cute and well made. I think the sole is a little too stiff for babies learning how to walk that are used to bare feet. The back of the sandal also slips down sometimes. Overall a decent purchase if you just need something for looks more than function.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 11, 2023
★★★★★ 5
Great first sandals
Special Size Type: Toddler (1-4 Years), Size: 18-24 Months Toddler, Color: Matthew Navy
Great quality, they are super cute and fit my toddler well.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 3, 2025
★★★★★ 5
Amazing first shoes
Special Size Type: Toddler (1-4 Years), Size: 18-24 Months Toddler, Color: Matthew Navy
These are a fantastic in between option for after moccs and before hard sole shoes. Research shows that barefoot is best for foot development, but living in AZ the ground is way too hot for Moccs in the summer. These are a great compromise since we don’t want to use hard soles for as long as possible. Love this brand and these sandals are so cute!
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 30, 2023
★★★★★ 5
Cute and Comfy
Special Size Type: Infant (0-12 Months), Size: 6-9 Months Infant, Color: Matthew Navy
My infant wore these for a few months, he’s 9 months now and they are too snug for 6-12 months size. We really liked the comfort and quality.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on July 16, 2022
★★★★★ 5
Little Blues
Special Size Type: Infant (0-12 Months), Size: 9-12 Months Infant, Color: Matthew Navy
Color was wonderful. The shoe is good quality. Loved the style. Cannot wait to see her wear them
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on August 12, 2024